ACRO

MacroGenics, Gilead Sciences to develop four DART products

Monday, January 7, 2013 01:47 PM

MacroGenics, a privately held biotechnology company that develops next generation antibody therapeutics, has entered into a license agreement with Gilead Sciences, a biopharmaceutical company focused on unmet medical needs, for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at up to four undisclosed targets.

More... »

Clinical research sites honor Eli Lilly, Medpace with Eagle Awards

Monday, October 15, 2012 11:57 AM

The 2012 Eagle Awards, presented to the top sponsor and top CRO as voted by clinical research sites, honored Eli Lilly and Medpace on Saturday, Oct. 13, at the annual Site Solutions Summit.

More... »

MacroGenics, Servier to develop three anti-cancer DART products

Friday, September 21, 2012 11:56 AM

MacroGenics, a Rockville, Md.-based privately held biotech that develops next generation antibody therapeutics, and Servier, a privately-held French pharmaceutical company, have entered into an option agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at three undisclosed tumor targets.

More... »

ACRO launches educational YouTube channel

Thursday, March 22, 2012 02:49 PM

In an effort to educate the public, media and policymakers about clinical trials and the growing role of CROs in the drug development process, the Association of Clinical Research Organizations (ACRO) has launched a YouTube channel @ACROHealthChannel.

More... »

Industry watchers nervous as PDUFA V deadline looms

Monday, November 21, 2011 08:02 AM

PDUFA IV expires Sept. 30, 2012, and several parties already are nervous about its renewal. 

More... »

Proposed Common Rule updates focus on consent, definitions, streamlined IRB review, data protection

Monday, October 31, 2011 08:02 AM

A 20-year-old federal policy for protecting human subjects known as the Common Rule is soon to be updated in ways that could modernize how the industry approaches the ethics, safety and oversight of human research.

More... »

Survey: Top CROs doubled workforce over past decade

Monday, October 24, 2011 08:02 AM

Over the last 10 years, the top nine global CROs have more than doubled their workforce, which now exceeds 72,000 employees, and their revenues have increased at a compound annualized rate of 11% as they increasingly play a larger and more integral role in the drug development infrastructure, according to a new Association of Clinical Research Organizations (ACRO) member survey.

More... »

Concerns grow over CMS missing Sunshine Act draft deadline as data collection start date looms

Monday, October 17, 2011 08:02 AM

Industry groups have expressed concern about the Centers for Medicare and Medicaid Services (CMS) missing its deadline for drafting regulations to implement the so-called sunshine law, which requires sponsors to publicly disclose payments to physicians and teaching hospitals. Pharmaceutical and biotechnology companies must begin collecting data to comply with the law in less than 11 weeks.

More... »

ACRO endorses Foreign Earnings Reinvestment Act

Wednesday, October 12, 2011 10:10 AM

The Association of Clinical Research Organizations (ACRO) supports the Foreign Earnings Reinvestment Act, bipartisan legislation introduced in the U.S. Senate last week by senators Kay Hagan (D-NC) and John McCain (R-AZ).

More... »

aCROnordic merges with Ecron Acunova

Wednesday, May 18, 2011 12:01 PM

Ecron Acunova, a full-service international CRO, will merge with Danish aCROnordic, specialized in Nordic clinical research.

More... »